Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Monoclonal Antibodies in the Treatment of Leukemia

Author(s): Susan O'Brien, Maher Albitar and Francis J. Giles

Volume 5, Issue 7, 2005

Page: [663 - 675] Pages: 13

DOI: 10.2174/156652405774641089

Price: $65

Abstract

MoAb-based therapies are evolving into the first broad-spectrum class of targeted antileukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAbs available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.

Keywords: Rituximab, cytotoxicity, hypertension, cyclophosphamide, Alemtuzumab


Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy